Brain Tumor Pathology

, Volume 33, Issue 1, pp 1–12

Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications

Review Article

Abstract

Metastases are the most common brain tumors especially in adults. Although they are generally considered a single disease entity which is universally fatal in patients with advanced cancer, brain metastases are remarkably heterogeneous both clinically and pathologically. As members of the multidisciplinary clinical team for the diagnosis and management of metastatic brain tumors, pathologists must be familiar not only with clinicopathologic features of brain metastases but also with any characteristic and clinically significant molecular findings. We discuss here the epidemiology, general gross and microscopic features of brain metastases with emphasis on how to differentiate them from primary brain tumors using immunohistochemistry (e.g., for identification of the primary site and differential diagnosis), and unique pathologic patterns of brain metastases (namely, dural metastasis, leptomeningeal carcinomatosis, miliary metastasis, “intravascular carcinomatosis”, and tumor-to-tumor metastasis) with their clinical and radiological characteristics. We specifically address metastatic breast and non-small cell lung cancers which are the two most commonly encountered in daily practice, with emphasis on the molecular alterations related to therapy and their clinicopathologic significance.

Keywords

Brain metastasis Immunohistochemistry Differential diagnosis Unique histologic patterns Molecular alterations 

References

  1. 1.
    Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48–54PubMedCrossRefGoogle Scholar
  2. 2.
    Iuchi T, Shingyoji M, Itakura M et al (2014) Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol 20:674–679PubMedCrossRefGoogle Scholar
  3. 3.
    Berghoff AS, Bago-Horvath Z et al (2013) Impact of Her-2-targeted therapy n overall survival in patients with Her-2 positive metastatic breast cancer. Breast J 19:149–155PubMedCrossRefGoogle Scholar
  4. 4.
    Dummer R, Goldinger SM, Turtschi CP et al (2014) Vemurafenib in patients with BRAF V600 mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50:611–621PubMedCrossRefGoogle Scholar
  5. 5.
    Beierwaltes WH, Lieberman LM, Varma VM, Counsell RE (1968) Visualizing human malignant melanoma and metastases. Use of chloroquine analog tagged with iodine 125. JAMA 206:97–102PubMedCrossRefGoogle Scholar
  6. 6.
    DeAngelis LM (1994) Management of brain metastases. Cancer Invest 12:156–165PubMedCrossRefGoogle Scholar
  7. 7.
    Nussbaum ES, Djalilian HR, Cho KH, Hall WA (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78:1781–1788PubMedCrossRefGoogle Scholar
  8. 8.
    Lagerwaard FJ, Levendag PC, Nowak PJ et al (1999) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795–803PubMedCrossRefGoogle Scholar
  9. 9.
    Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239–1246PubMedCrossRefGoogle Scholar
  10. 10.
    Skibber JM, Soong SJ, Austin L et al (1996) Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3:118–123PubMedCrossRefGoogle Scholar
  11. 11.
    Kolomainen DF, Larkin JM, Badran M et al (2002) Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol 20:982–986PubMedCrossRefGoogle Scholar
  12. 12.
    Tremont-Lukats IW, Bobustuc G, Lagos GK et al (2003) Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer 98:363–368PubMedCrossRefGoogle Scholar
  13. 13.
    Hjiyiannakis P, Jefferies S, Harmer CL (1996) Brain metastases in patients with differentiated thyroid carcinoma. Clin Oncol (R. Coll Radiol) 8:327–330CrossRefGoogle Scholar
  14. 14.
    Fox BD, Patel A, Suki D, Rao G (2009) Surgical management of metastatic sarcoma to the brain. J Neurosurg 110:181–186PubMedCrossRefGoogle Scholar
  15. 15.
    Kebudi R, Ayan I, Görgün O et al (2005) Brain metastasis in pediatric extracranial solid tumors: survey and literature review. J Neurooncol 71:43–48PubMedCrossRefGoogle Scholar
  16. 16.
    Curless RG, Toledano SR, Ragheb J et al (2002) Hematogenous brain metastasis in children. Pediatr Neurol 26:219–221PubMedCrossRefGoogle Scholar
  17. 17.
    Parker GD, Hamsberger HR (1991) Clinical-radiologic issues in perineural tumor spread of malignant diseases of the extracranial head and neck. Radiographics 11:383–399PubMedCrossRefGoogle Scholar
  18. 18.
    Porter AT, David M (2007) Palliative care for bone, spinal cord, brain and liver metastases. In: Gunderson LL, Tepper JE (eds) Clinical radiation oncology. Elsevier, Philadelphia, pp 437–455Google Scholar
  19. 19.
    Narayana A, Liebel SA (2004) Primary and metastatic brain tumors. In: Liebel SA, Phillips TL (eds) Textbook of radiation oncology. Elsevier, Philadelphia, pp 463–495Google Scholar
  20. 20.
    Nonaka H, Akima M, Hatori T et al (2003) The microvascular of the cerebral white matter: arteries of the subcortical white matter. J Neuropathol Exp Neurol 62:154–161PubMedGoogle Scholar
  21. 21.
    Hwang TL, Close TP, Grego JM et al (1996) Predilection of brain metastasis in gray and white matter junction and vascular border zones. Cancer 77:1551–1555PubMedCrossRefGoogle Scholar
  22. 22.
    Fowler BZ, Crocker IR, Johnstone PAS (2005) Perineural spread of cutaneous malignancy to the brain. A review of the literature and five patients treated with stereotactic radiotherapy. Cancer 103:2143–2153PubMedCrossRefGoogle Scholar
  23. 23.
    Pekmezci M, Perry A (2013) Neuropathology of brain metastasis. Surg Neurol Int 4(Suppl 4):S245–S255PubMedPubMedCentralGoogle Scholar
  24. 24.
    Tacha D, Qi W, Ra S et al (2015) A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas. Arch Pathol Lab Med 139:530–536PubMedCrossRefGoogle Scholar
  25. 25.
    Carney EM, Banerjee P, Ellis CL et al (2011) PAX2(−)/PAX8(−)/inhibin A(+) immunoprofile in hemangioblastoma: a helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. Am J Surg Pathol 35:362–367Google Scholar
  26. 26.
    Kawakami F, Takei H (2015) Central nervous system metastasis. In: Rivera A, Takei H (eds) Advances in surgical pathology. Brain cancer. Wolter Kluwer, Philadelphia, pp 189–196Google Scholar
  27. 27.
    Posner JB, Chernik NL (1978) Intracranial metastases from systemic cancer. In: Schoenberg BS (ed) Advances in neurology. Raven Press, New York, pp 579–592Google Scholar
  28. 28.
    Takakura K, Sano K, Hojo S, Hirano A (1982) Metastatic tumors of the central nervous system. Igaku-shoin, TokyoGoogle Scholar
  29. 29.
    Nayak L, Abrey LE, Iwamoto FM (2009) Intracranial dural metastases. Cancer 115:1947–1953PubMedCrossRefGoogle Scholar
  30. 30.
    Laigle-Donadey F, Taillibert S, Mokhtari K et al (2005) Dural metastases. J Neurooncol 75:57–61PubMedCrossRefGoogle Scholar
  31. 31.
    Caputi F, Lamaida E, Gazzeri R (1999) Acute subdural hematoma and pachymeningitis carcinomatosa: case report. Rev Neurol (Paris) 155:383–385Google Scholar
  32. 32.
    Turner DM, Graf CJ (1982) Nontraumatic subdural hematoma secondary to dural metastasis: case report and review of the literature. Neurosurgery 11:678–680PubMedCrossRefGoogle Scholar
  33. 33.
    Bucci MN, Farhat SM (1986) Metastatic adenocarcinoma of the prostate as a cause of subdural hematoma. J Urol 135:803–804PubMedGoogle Scholar
  34. 34.
    Russell DS, Cairns H (1934) Subdural false membrane or haematoma (pachymeningitis interna haemorrhagica) in carcinomatosis and sarcomatosis of the dura mater. Brain 57:32–48CrossRefGoogle Scholar
  35. 35.
    Pace A, Fabi A (2006) Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 60:194–200PubMedCrossRefGoogle Scholar
  36. 36.
    Chowdhary S, Chamberlain M (2005) Leptomeningeal metastases: current concepts and management guidelines. J Natl Compr Cancer Netw 3:693–703Google Scholar
  37. 37.
    Glass JP, Melamed M, Chernik NL, Posner JB (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375PubMedCrossRefGoogle Scholar
  38. 38.
    Jaeckle KA (2006) Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol 33:312–323PubMedCrossRefGoogle Scholar
  39. 39.
    Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772PubMedCrossRefGoogle Scholar
  40. 40.
    Kaplan JG, DeSouza TG, Farkash A et al (1990) Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 9:225–229PubMedCrossRefGoogle Scholar
  41. 41.
    Amer MH, Al-Sarraf M, Baker LH, Valtkevicius VK (1978) Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42:660–668PubMedCrossRefGoogle Scholar
  42. 42.
    Niwińska A, Rudnicka H, Murawska M (2013) Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol 30:408PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Yap HY, Yap BS, Tashima CK, DiStefano A, Blumenschein GR (1978) Meningeal carcinomatosis in breast cancer. Cancer 42:283–286PubMedCrossRefGoogle Scholar
  44. 44.
    Chamberlain MC (2005) Neoplastic meningitis. J Clin Oncol 23:3605–3613PubMedCrossRefGoogle Scholar
  45. 45.
    Subira D, Simo M, Illan J et al (2015) Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis. Clin Exp Metastasis 32:383–391PubMedCrossRefGoogle Scholar
  46. 46.
    Garson JA, Coakham HB, Kemshead JT et al (1985) The role of monoclonal antibodies in brain tumour diagnosis and cerebrospinal fluid (CSF) cytology. J Neurooncol 3:165–171PubMedCrossRefGoogle Scholar
  47. 47.
    Hovestadt A, Henzen-Logmans SC, Vecht CJ (1990) Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis. Br J Cancer 62:653–654PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Boogerd W, Vroom TM, van Heerde P et al (1988) CSF cytology versus immunohistochemistry in meningeal carcinomatosis. J Neurol Neurosurg Psychiatry 51:142–145PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Madow L, Alpers BJ (1951) Encephalitic form of metastatic carcinoma. AMA Arch Neurol Psychiatry 65:161–173PubMedCrossRefGoogle Scholar
  50. 50.
    Ogawa M, Kurahishi K, Ebina A et al (2007) Miliary brain metastasis presenting with dementia: progression pattern of cancer metastases in the cerebral cortex. Neuropathology 27:390–395PubMedCrossRefGoogle Scholar
  51. 51.
    Iguchi Y, Mano K, Goto Y et al (2007) Miliary brain metastases from adenocarcinoma of the lung: MR imaging findings with clinical and post-mortem histopathologic correlation. Neuroradiology 49:35–39PubMedCrossRefGoogle Scholar
  52. 52.
    Kahveci R, Gurer B, Kaygusuz G, Sekerci Z (2012) Miliary brain metastases from occult lung adenocarcinoma: radiologic and histopathologic confirmation. J Neurosci Rural Pract 3:386–389PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Hutchings M, Weller RO (1986) Anatomical relationships of the pia mater to cerebral blood vessels in man. J Neurosurg 65:316–325PubMedCrossRefGoogle Scholar
  54. 54.
    Zhang ET, Inman CBE, Weller RO (1990) Interrelationships of the pia mater and the perivascular (Virchow–Robin) spaces in the human cerebrum. J Anat 170:111–123PubMedPubMedCentralGoogle Scholar
  55. 55.
    Takei H, Rouah E, Barrios R (2015) Intravascular carcinomatosis of central nervous system due to metastatic inflammatory breast cancer: a case report. Neuropathology 35:456–461PubMedCrossRefGoogle Scholar
  56. 56.
    Campbell LV, Gilbert E, Chamberlein CR, Watne AL (1968) Metastases of cancer to cancer. Cancer 22:635–643PubMedCrossRefGoogle Scholar
  57. 57.
    Pamphlett R (1984) Carcinoma metastasis to meningioma. J Neurol Neurosurg Psychiatry 47:561–563PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Erdogan H, Aydin MV, Tasdemiroglu E (2014) Tumor-to-tumor metastasis of the central nervous system. Turk Neurosurg 24:151–162PubMedGoogle Scholar
  59. 59.
    Hamazaki S, Nakashima H, Matsumoto K et al (2001) Metastasis of renal cell carcinoma to central nervous system hemangioblastoma in two patients with von Hippel-Lindau disease. Pathol Int 51:948–953PubMedCrossRefGoogle Scholar
  60. 60.
    Mottolese C, Stan H, Giordano F et al (2001) Metastasis of clear-cell renal carcinoma to cerebellar hemangioblastoma in von Hippel-Lindau disease: rare or not investigated. Acta Neurochir (Wien) 143:1059–1063CrossRefGoogle Scholar
  61. 61.
    Chambers PW, Davis RL, Blanding JD, Buck FS (1980) Metastases to primary intracranial meningiomas and neurilemmomas. Arch Pathol Lab Med 104:350–354PubMedGoogle Scholar
  62. 62.
    Li Z, Lu J, Zhao Y, Guo H (2011) The retrospective analysis of the frequency of EGFR mutations and efficacy of gefitinib in NSCLC patients with brain metastases. J Clin Oncol 29:e18065Google Scholar
  63. 63.
    Rangachari D, Yamaguchi N, VanderLaan PA et al (2015) Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88:108–111PubMedCrossRefGoogle Scholar
  64. 64.
    Zhang J, Yu J, Sun X, Meng X (2014) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer. Cancer Lett 351:6–12PubMedCrossRefGoogle Scholar
  65. 65.
    Camidge DR, Bang YJ, Kwak EL (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase I study. Lancet Oncol 13:1011–1019PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Otterson GA, Riely GJ, Shaw AT (2012) Clinical characteristics of ALK + NSCLC patients treated with crizotinib beyond disease progression: potential implications for management. Proc Am Soc Clin Oncol 30(Suppl):abstract 7600Google Scholar
  67. 67.
    Guerin A, Sasane M, Zhang J et al (2015) Brain metastasis in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ 18:321–322Google Scholar
  68. 68.
    Gainor JF, Ignatius S-H, Logan J, Borges LF, Shaw AT (2013) The central nervous system as a sanctuary site in ALK-positive non-small cell lung cancer. J Thorac Oncol 8:1570–1573PubMedCrossRefGoogle Scholar
  69. 69.
    Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913–920PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Kennecke H, Yerushalmi R, Woods R et al (2012) Metastatic behavior of breast cancer subtype. J Clin Oncol 28:3271–3277CrossRefGoogle Scholar
  71. 71.
    Gil-Gil MJ, Martinez-Garcia M, Sierra A et al (2014) Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol 16:436–446PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Shen Q, Sahin AA, Hess KR et al (2015) Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist 20:466–473PubMedCrossRefGoogle Scholar
  73. 73.
    Van Poznak C, Somerfield MR, Bast RC et al (2015) Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 33:2695–2704PubMedCrossRefGoogle Scholar
  74. 74.
    Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. CAP www.cap.org/apps/docs/committees/…/her2_faqs.pdf. Accessed 25 Aug 2015

Copyright information

© The Japan Society of Brain Tumor Pathology 2015

Authors and Affiliations

  1. 1.Department of Diagnostic PathologyAsahikawa Medical UniversityAsahikawaJapan
  2. 2.Department of Pathology and ImmunologyBaylor College of MedicineHoustonUSA
  3. 3.Department of Clinical Pathology, Graduate School of MedicineHokkaido UniversitySapporoJapan

Personalised recommendations